Evaluating the Impact of Point-of-Care Electroencephalography on Length of Stay in the Intensive Care Unit: Subanalysis of the SAFER-EEG Trial
Desai M, Kalkach-Aparicio M, Sheikh I, Cormier J, Gallagher K, Hussein O, Cespedes J, Hirsch L, Westover B, Struck A. Evaluating the Impact of Point-of-Care Electroencephalography on Length of Stay in the Intensive Care Unit: Subanalysis of the SAFER-EEG Trial. Neurocritical Care 2024, 1-10. PMID: 38981999, DOI: 10.1007/s12028-024-02039-6.Peer-Reviewed Original ResearchIntensive care unitIntensive care unit LOSNonconvulsive seizuresClinical outcomesFunctional outcomesCare unitDetection of nonconvulsive seizuresInterquartile rangeAssociated with neuronal injuryDiagnose nonconvulsive seizuresIntensive care unit patientsUnfavorable functional outcomeMann-Whitney U testProlonged nonconvulsive seizuresPropensity score matchingDeleterious clinical outcomesClinical characteristicsAdult patientsRandomized studyConventional EEGICU LOSNeuronal injuryFunctional/clinical outcomesAcademic centersClinical covariatesSecond‐line immunotherapy in new onset refractory status epilepticus
Hanin A, Muscal E, Hirsch L. Second‐line immunotherapy in new onset refractory status epilepticus. Epilepsia 2024, 65: 1203-1223. PMID: 38430119, DOI: 10.1111/epi.17933.Peer-Reviewed Original ResearchFebrile infection-related epilepsy syndromeSecond-line immunotherapyOnset refractory status epilepticusRefractory status epilepticusIntrathecal dexamethasoneStatus epilepticusCytokine levelsFunctional outcomesCerebrospinal fluid cytokine levelsInitiation of anakinraReduction of seizure frequencyLong-term functional outcomeResponse to treatmentSE onsetElevated serumFebrile infectionsImmune dysregulationLong-term disabilityTreatment initiationCase reportCytokine measurementsProspective studyAnakinraImmunotherapyTocilizumab